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8.1* What name(s) did the doctor use to describe the
child's chest problem? (record)
8.2* Where did the child go for treatment for this chest
problem? (private doctor, day hospital, Red Cross
Hospital, other hospital or clinic, other (specify»
9*. Is the child currently on any treatment for any of the
following: wheezing/whistling in the chest, tight chest,
night cough or asthma?
9.1* If yes what treatment? (tablets, syrup, inhaler,
nebuliser (oxygen), injection, other (specify»
10.* Do you know of anything you can do inside the child's
bedroom to prevent allergy or breathing problems? (record)
11.* Do you know of anything your child can avoid eating or
drinking so as to prevent allergy or breathing problems?
(record)
12.* Has the child ever been asked by a doctor or nurse to
blow into a peak flow meter? (show picture of meter)
13.* Has the child ever had asthma?
13.1* Does s/he still have asthma?
• Interview (2nd) questionnaire only.
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LUNG FUNCTION IN SOUTH
AFRICAN CHILDREN WITH CYSTIC
FIBROSIS
H J Zar, B Moore, A Argent, J Ireland, A T R Westwood
Objediue. To determine the pattern of lung function in stable
cystic fibrosis (CF) patients and to investigate the relatiooship
of abnormal hmg function to demographic variables, CF
genotype and puImoIIary colonisation with PseudomtnrIls
~(pA).
Design. A descriptive study done at the CF ctinic at Red Cross
War Memorial QWdren's Hospital in Cape Town.
Methods. Datawere recorded and pulmonary function testing
(PFI) was perfomled in 42 CF patients.
RtsulIs. 29 patients (69%) had mild diseiIse,. while 11 (26%)
and 2 (5%) had moderate and severe disease~
Twenty-four patients (57'%) demoltstridled lower airway
obstuKDoo (LAO). Patients with moderate or severe disease
were significantly older than those with mild disease (133
(3.7) years (mean (SD» oompared with 11.1 (3.0) years
(t =2.1; P =OM». PA mIonisation status ctiffer'ed
significantly with the patIIem of lung function <r =6.6; P =
0.04) and severity of lung disease <r =12.6; P =0.002.). Nine
(35%) of the 26 patients tesIed before and afterbroncbodilator
therapy showed a positive n:spoose.
ConcbIsiorL The majority of patients had mildly impaired or
normal lung fuDction. withLAD predominating. A minority
of patients were bmncbodilatoMesponsive. PA colonisation
may be associated with the deveIopmeut of abnormal lung
function and DKlIe severe pnJmmary disease..
sAIrIIIIi'llJ1lll; .9M-991.
Cystic fibrosis (CF) is one of the most common serious
inherited disorders among South Africa's white and coloured
populations' and may be more common than formerly realised
in the black population! Clinical manifestations include
pancreatic insufficiency, hepatic dysfunction, infertility and
pulmonary disease. Of these, pulmonary disease, characterised
by endobronchial bacterial infection and neutrophil-dominated
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inflammation, is the major cause of morbidity and mortality.
Staphylococcus aureus and Haemophilus influenzae are the initial
respiratory pathogens, while Pseudomonas aeruginosa (PA)
predominates later.'
The extent, progression and reversibility of pulmonary
disease may be assessed reliably using pulmonary function
testing (PIT). PIT may also be used to predict prognosis. The
forced vital capacity (FVC) and forced expiratory volume in
1 second (FEVl ) are significant predictors of survival in CF
patients'
South African patients with CF have a less favourable
prognosis than their European or North American
counterparts, with a median survival of 18 years.' Although
many deaths occur in infancy, more rapidly progressive lung
disease may partly account for these differences. However
there are a paucity of data on lung function in South African
CF patients, with a single descriptive study published." We
report on the pattern and reversibility of lung function in stable
CF patients. We investigated the relationship of lung function
to demographic variables, CF genotype and pulmonary
colonisation with PA.
METHODS
Patients older than 5 years attending the CF clinic at Red Cross
War Memorial Children's Hospital in Cape Town were
consecutively entered into the study. Patients were excluded if
they could not reliably perform PIT or if they had had a
pulmonary exacerbation within the preceding month. Patients
currently attending the clinic received treatment as outlined in
Table I.
Data recorded included age, sex, CF genotype, pancreatic
furICtion and sputum culture results. PA colonisation was
defined as three positive sputum cultures within the preceding
year. PIT was performed by the same technician with
spirometry (Vitalograph Spirometer, Vitalograph Ltd, England)
Table L Current treatment for pulmonary disease in CF patients at Red Cross War Memorial Children's Hospital
Indication Therapy Comment
Flucloxacillin twice a day
Antibiotics effective against PA for
2 weeks
Chest physiotherapy
Antibiotics for 2 weeks
Chest physiotherapy
Inhaled bronchodilators if responsive
bacteria
Pulmonary exacerbation
General maintenance of optimal Pancreatic enzyme replacement therapy For pancreatic-insufficient patients
clinical condition Nutritional support Emphasis on adequate diet and nutritional
supplements
May prevent development of pulmonary
complications and airway obstruction
Use of prophylaxis is controversial
Aggressive long-term anti-Pseud0m0n4s
therapy to delay onset of infection used
by Danish CF centre
Antibiotics given orally or intravenously
depending on severity of exacerbation
Use antibiotics effective against colonising
Improvement of mucociliary
clearance
Prevention of S. aureus colonisation




Prophylaxis for influenza virus
Aminoglycoside inhalations
Ibuprofen daily
Inhaled bronchodilators for relief of
acute attacks
Inhaled anti-inflammatory agents for
prophylaxis of moderate or severe asthma
Annual influenza vaccine
Two antibiotics should be used for PA
May reduce clinical symptoms and improve
lung function
Routine use of:Hnonthly intravenous
antibiotics used by Danish CF centre
Most effective in young patients
High doses necessary for efficacy; regular
monitoring of plasma levels required
Increased incidence of airway hypeneactivity
in CF patients, but variable response to
bronchodilators
Other therapies not routinely available
Reduction in sputum viscosity rhO ase
Improvement of mucociliary Inhaled hypertonic (6%) saline
clearance
Most useful for patients with obstructive
lung disease, purulent airway secretions and
endobronchial bacterial infection
Usefulness limited by cost
Improves lung function but response variable
Reported to improve lung function but
further studies needed to confirm this
••
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Table IT. Patterns of lun--& function in patients with CF
(% predicted) (mean (SO»
DISCUSSION
This study indicates that the majority of our CF patients have
mild lung disease, with the most common abnormality being
LAO. This may reflect a relatively young patient population as
pulmonary disease initially produces airway obstruction. With
progression of infection and inflammation, fibrosis and
restrictive lung disease occur." Another possibility is that we
selected relatively healthy patients. The sample included
patients older than 5 years of age; it is therefore possible that
patients who are more ill and who die younger would not have
participated in the study. However currently very few of our
patients die during early childhood. In addition the sample
comprised the majority (86%) of patients older than 5 years
enrolled as patients at the CF diIlic. Consistent with previous
reports, we did not find a relationship between genotype and
the pattern or severity of lung function.' Older patients had
more severe lung disease, reflecting the reported yearly decline
in pulmonary function. IQ
Airway obstruction was illdicated maiIlly by a decrease ill
FEF25-7S- illdicating that the site of obstruction is the peripheral
moderate and severe disease respectively. Patients with
moderate or severe disease were significantly older than those
with mild disease (13.3 (3.7) years compared with 11.1 (3.0)
years (t = 2.1; P = 0.04).
Pattern of lung function did not differ significantly accordiIlg
to gender or CF genotype. PA colonisation status differed
significantly with the pattern of lung function
(X' = 6.6; P = 0.04) and severity of lung disease (X' = 12.6;
P = 0.002). Of the 16 patients colonised with PA, 2 (13%) had
normal function; 13 (81%) and 1 (6%) had obstructive and
restrictive patterns respectively. In contrast, of the 26 patients
not colonised with PA, 13 (50%) had normal lung function. The
majority (77%) of patients with moderate or severe lung
disease were colonised with PA, whereas 79% of patients with
mild disease were not.
ine (35%) of the 26 patients tested before and after
bronchodilator administration showed a positive response.
Thirty per cent of patients with LAO demonstrated
reversibility. There was no relationship between the severity of
lung disease and bronchodilator response, and no patient








(N = 24) (N = 3)
70.3 (18.6) 71.3 (15.0)
59.1 (21.1) 69.3 (13.3)




using the forced expiratory manoeuvre. FVC and FEV] were
measured, and forced expiratory flow at 25 - 75% of the FVC
(FEF25-7S) was calculated. All values were expressed as a
percentage of predicted normal values.7
Lung function was considered normal when the lung
volumes and the expiratory flow rates were within predicted
normal limits and proportional to each other. A restrictive
pattern was defined as FVC less than or equal to 85% of the
predicted normal value, with a proportionate decrease in the
expiratory flow rates. Lower airway obstruction (LAO) was
defined as a FEV] or FEF25-7S below 2 standard deviations (SO)
from the predicted normal value and disproportionately
decreased relative to FVC (FEV1/FVC < 70% or FEF25-7S (%
predicted)/FVC (% predicted) ~ 0.8. Pulmonary disease was
further classified as mild (FVC 2: 70% of the predicted value),
moderate (FVC 40 - 69% of the predicted value) and severe
(FVC < 40% of the predicted value).
The effect of a brochodilator was assessed by measuring the
change ill PFr 20 mllutes after inhalation of 200 llg fenoterol
via dry powder device (Berotec inhalets; Boehringer
Ingelheim). A positive response was defined as an increase
from baseliIle in any of the following indices: FVC of 10%,
FEV] of 15% or FEF25-7S of 20%.
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS). One-way ANOVA was
used to compare groups with different patterns (obstructive,
restrictive, or normal) and severity (mild, moderate, severe) of
lung function in terms of age and lung indices (FVC, FEV]
FEF25-7S)' The chi-square test was used to determine whether
the pattern and severity of lung function differed accordiIlg to
gender (male, female), CF genotype (8F508 homozygous,
8F508 heterozygous with another CF mutation or two non-
8F508 CF mutations) and PA colonisation status.
RESULTS
The 42 patients (22 male) who participated in this study
represent 65% of CF patients attendiIlg our diIlic and 86% of
those eligible for the study. Three eligible patients did not
participate as they were unable to perform PFr, while 4 did not
visit the diIlic during the study period. The mean age was 11.8
years (range 5.9 - 18.8 years). Forty (95%) of the patients were
pancreatic-insufficient. Seventeen (41%) of the patients were
8F508 homozygous, 18 (43%) were 8F508 heterozygous with
another CF mutation, 5 (12%) had two non-8F508 CF
mutations, and 2 were not genotyped. Sixteen patients (38%)
were colonised with PA.
Twenty-four patients (57%) demonstrated LAO, 3 (7%) had a
restrictive pattern and 15 (36%) had normal lung function.
Table IT presents the indices of lung function in these groups,
which did not differ significantly in terms of age or gender.
When the severity of lung function was classified by FVC, 29
patients (69%) had mild disease while 11 (26%) and 2 (5%) had




airways. FEF2S-75 is a sensitive indicator of small-airways
disease, deteriorating before changes in FEV! or FVC become
apparent.s Only a small number of patients demonstrated
reversibility of LAO with bronchodilators. The poor response
that we found may be multifactorial. Airway obstruction in CF
is caused by thickened secretions, endobronchial infection and
inflammation and bronchial hyperreactivity to various stimulill
Of these, bronchial hyperreactivity may respond to
bronchodilator therapy. Other studies have reported that
between 0% and 95% of patients respond to bronchodilators.1w
Differences in patient population, in the definition of response
and in the method of administration of bronchodilator may
also explain our low response rate. We used a low dose (200
llg) of 13Tagonist via a dry powder device, while others have
used higher doses via nebuliser or metered dose inhaler.
However we chose to evaluate bronchodilator response with
the device most frequently prescribed for patients. Patients
may also demonstrate variable responses to bronchodilators
with repeated PFT; thus longitudinal testing results in higher
numbers of responders." Chronic bronchodilator therapy
should therefore be based on results of repeated tests.
In most CF centres PA is the predominant respiratory
pathogen in patients by the end of the first decade of life.15 The
majority of patients acquire PA during their lifetime and rarely,
if ever, eradicate it from their lungs. l • Thirty-eight per cent of
our patients were colonised with this organism compared with
more than 50% of similarly aged North American children with
CF.17 Differences in environmental exposure to Pseudomonas, in
antibiotic usage or in methods of obtairIing and culturirlg
sputum specimens may account for some of these differences.
Despite our lower colonisation rates there was a significant
association between infection with PA and abnormal lung
function. Chronic pulmonary colonisation with PA has been
associated .....rith pulmonary deterioration and a poorer
prognosiS.15•IS Hoiby15.19 has suggested that PA colonisation leads
to rapid clinical deterioration; others, however, have reported a
more gradual and variable process.'" Our data are consistent
with a causal relationship between PA colonisation and the
development of abnormal lung function and more severe
pulmonary disease.
Although South African CF patients have been reported to
have a worse prognosis than their American or European
counterparts/ this study indicates that PA infection and more
severe lung disease do not explain the differences in mortality.
Other factors such as delay in CF diagnosis, worse nutritional
status, poorer socio-econornic conditions and access to health
care may impact on survival. Another possibility is that young
patients who are severely ill may die before 5 years of age and
so would not form part of the group of patients we studied.
Furthermore, advances in our understanding of CF and newer
and more effective therapies may have resulted in improved
prognosis compared with that which has been reported.
We thank Ms Felicity Leisegang, Department of Chemical
Pathology, Red Cross Children's Hospital, for performing CF
genotyping.
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